Kymera Therapeutics Quarterly Balance Sheet
NASDAQ: KYMRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kymera Therapeutics financial position
As of Jun 30, 2026, Kymera Therapeutics reported total assets of $1.65 billion, up 45.5% from a year earlier against total liabilities of $136.2 million. Shareholders' equity stood at $1.51 billion, or 91.7% of assets. The company held $124.5 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 10.34, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Kymera Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 124.48M | 144.09M | 357.01M | 112.95M | 335.82M | 89.97M | 120.26M | 110.72M | 67.61M | 93.51M | 109.97M | 81.05M |
| Short-Term Investments | 566.51M | 506.84M | 491.26M | 392.73M | 329.63M | 373.18M | 368.49M | 439.25M | 442.34M | 427.03M | 264.92M | 276.77M |
| Receivables | 20.00M | — | 0 | — | 40.00M | — | 0 | 0 | 0 | 0 | 15.00M | — |
| Total Current Assets | 737.26M | 677.43M | 871.21M | 528.30M | 728.33M | 500.95M | 510.27M | 568.72M | 525.41M | 537.25M | 405.32M | 375.69M |
| Property, Plant & Equipment | 39.97M | 41.62M | 43.17M | 45.13M | 48.57M | 49.17M | 50.46M | 51.24M | 51.73M | 49.34M | 48.13M | 36.15M |
| Long-Term Investments | 813.90M | 894.72M | 771.16M | 473.06M | 297.63M | 312.33M | 362.16M | 361.04M | 192.44M | 224.39M | 61.43M | 76.99M |
| Total Assets | 1.65B | 1.67B | 1.74B | 1.10B | 1.13B | 918.31M | 978.03M | 1.03B | 826.02M | 868.25M | 575.76M | 552.38M |
| Accounts Payable | 8.92M | 12.84M | 4.01M | 5.51M | 5.78M | 10.26M | 5.99M | 6.49M | 6.51M | 6.81M | 7.08M | 4.98M |
| Total Current Liabilities | 71.33M | 62.64M | 83.21M | 71.58M | 87.54M | 58.99M | 67.77M | 66.53M | 62.14M | 56.14M | 85.69M | 63.17M |
| Total Liabilities | 136.19M | 129.38M | 163.15M | 155.79M | 159.59M | 132.08M | 142.42M | 141.91M | 141.10M | 157.05M | 180.79M | 156.84M |
| Shareholders' Equity | 1.51B | 1.54B | 1.58B | 946.26M | 971.48M | 786.23M | 835.62M | 892.93M | 684.92M | 711.20M | 394.97M | 395.54M |
| Retained Earnings | -1.20B | -1.14B | -1.07B | -978.98M | -896.80M | -820.19M | -754.61M | -683.86M | -621.37M | -579.31M | -530.75M | -516.38M |
| Net Cash (Debt) | 690.99M | 650.93M | 848.28M | 505.68M | 665.45M | 463.15M | 488.74M | 549.97M | 509.95M | 520.54M | 374.88M | 357.82M |
| Shares Outstanding | 82.79M | 82.18M | 81.32M | 71.74M | 70.56M | 65.11M | 64.89M | 64.75M | 61.57M | 61.35M | 55.59M | 55.45M |
This table shows 12 quarterly periods of Kymera Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 14 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow KYMR's reporting calendar. What is a balance sheet?